Nuclear Medicine Program progress report for quarter ending June 30, 1992

Technical Report · Sat Aug 01 04:00:00 EDT 1992

OSTI ID:7262958

Ambrose, K R; Callahan, AP; McPherson, D W; Mirzadeh, S; Hasan, A; Lambert, C R; Rice, D E; Srivastava, P C

In this report the results of preliminary studies of pancreatic exocrine function in normal patients and volunteers by a simple urine analysis using a new iodine-131-labeled triglyceride are described. The new ORNL agent, 1,2-dipalmitoyl-3-((15-piodophenyl)pentadecan-l-oyl)-rac-glycerol (1,2-Pal-3-IPPA) was radiolabeled with iodine-131 and used in clinical studies in a collaborative program with the Clinic for Nuclear Medicine at the University of Bonn, Germany. The observed rapid urinary excretion of high levels of the orally administered test agent from patients corroborated results from initial studies conducted in laboratory animals (ORNL/TM-12110). In the initial group of normal volunteers and 11 patients with normal pancreatic function an average of 76 {plus minus} 13.8% of the administered activity was excreted in the urine in 24 h. Studies will now also focus on evaluation of this agent in patients with pancreatic insufficiency. The reactor production of dysprosium-166 in the ORNL High Flux Isotope Reactor (HFIR) and the separation of carrier-free holmium-166 have also been pursued. Holmium-166 (t{sub {1/2}}226.4 h) decays with the emission of high energy beta particles and abundant secondary electrons and is thus of interest for various therapeutic applications. Four-day irradiation of {sup 165}Ho in the HFIR resulted in production of {sup 166}Ho with a specific activity of 7.25 mCi/mg. The formation of {sup 166}Ho by beta-decay of reactor-produced {sup 166}Dy was also evaluated. The specific activity of {sup 166}Dy for an 8-day HFIR irradiation was 3.5 mCi/mg. Preliminary results indicate that carrier-free {sup 166}Ho can be separated from the neutron-irradiated target by HNO{sub 3} elution from di-(2-ethylhexyl)phosphoric acid (HDEHP) impregnated glass beads.

• Research Organization: Oak Ridge National Lab., TN (United States)
• Sponsoring Organization: DOE; USDOE, Washington, DC (United States)
• DOE Contract Number: AC05-84OR21400
• OSTI ID: 7262958
• Report Number(s): ORNL/TM-12159; ON: DE92040486
• Country of Publication: United States
• Language: English

Related Subjects

550603 -- Medicine-- External Radiation in Therapy-- (1980-)
550604* -- Medicine-- Unsealed Radionuclides in Therapy-- (1980-)
62 RADIOLOGY AND NUCLEAR MEDICINE
BETA DECAY RADIOISOTOPES
BETA-MINUS DECAY RADIOISOTOPES
BIOLOGICAL MATERIALS
BIOLOGICAL WASTES
BODY
BODY FLUIDS
CLEARANCE
DAYS LIVING RADIOISOTOPES
DIAGNOSTIC USES
DIGESTIVE SYSTEM
DOCUMENT TYPES
DRUGS
DYSPROSIUM 166
DYSPROSIUM ISOTOPES
ENDOCRINE GLANDS
ESTERS
EVEN-EVEN NUCLEI
EXCRETION
GLANDS
HOLMIUM 166
HOLMIUM ISOTOPES
INTERMEDIATE MASS NUCLEI
ISOMERIC TRANSITION ISOTOPES
ISOTOPE PRODUCTION
ISOTOPES
LABELLED COMPOUNDS
LIPIDS
MATERIALS
NUCLEI
ODD-ODD NUCLEI
ORGANIC COMPOUNDS
ORGANS
PANCREAS
PATIENTS
PROGRESS REPORT
RADIOISOTOPE GENERATORS
RADIOISOTOPES
RADIOPHARMACEUTICALS
RARE EARTH ISOTOPES
RARE EARTH NUCLEI
SECONDS LIVING RADIO
TRIGLYCERIDES
URINE
USES
WASTES